Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review
Satoru Okada, Shunta Ishihara, Tatsuo Furuya, Chiaki Nakazono, Masayoshi Inoue · 2026
Read Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review by Satoru Okada, Shunta Ishihara, Tatsuo Furuya, Chiaki Nakazono, Masayoshi Inoue (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13346031.txt.
Description
Satoru Okada and colleagues reviewed in 2026 the biology of thymic epithelial tumours and how immune features should shape treatment. These rare chest tumours include thymomas, often linked to autoimmune diseases such as myasthenia gravis, and the more aggressive thymic carcinomas.
Complete surgical removal remains the mainstay for all types, with radiation and drug therapy playing larger roles in advanced or recurrent disease. Drawing on a broad literature search plus their own research, the authors contrasted how thymoma and carcinoma differ in immune behaviour and drug sensitivity. The synthesis aims to match each tumour type to the strategy most likely to help, including immunotherapy choices where autoimmune risk must be weighed carefully.
Catalog record
| CREATOR | Satoru Okada, Shunta Ishihara, Tatsuo Furuya, Chiaki Nakazono, Masayoshi Inoue |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |